{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:38:20Z","timestamp":1707525500489},"reference-count":43,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,24]]},"DOI":"10.7759\/cureus.49351","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T16:54:21Z","timestamp":1700844861000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Immunosuppression: The Intricate Relationship Between Tacrolimus and Microangiopathy"],"prefix":"10.7759","author":[{"given":"Ripudaman S","family":"Munjal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinija","family":"Polishetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushkar Sai","family":"Valleru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshi","family":"Banker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramansh","family":"Bandhu Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FNU","family":"Anamika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi1947.117.8_542","article-title":"[Discovery and development of a novel immunosuppressant, tacrolimus hydrate]","volume":"117","author":"Tanaka H","year":"1997","unstructured":"Tanaka H, Nakahara K, Hatanaka H, Inamura N, Kuroda A. [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. Yakugaku Zasshi. 1997, 117:542-54. 10.1248\/yakushi1947.117.8_542","journal-title":"Yakugaku Zasshi"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i1.144","article-title":"Overview of extended release tacrolimus in solid organ transplantation","volume":"6","author":"Patel N","year":"2016","unstructured":"Patel N, Cook A, Greenhalgh E, Rech MA, Rusinak J, Heinrich L. Overview of extended release tacrolimus in solid organ transplantation. World J Transplant. 2016, 6:144-54. 10.5500\/wjt.v6.i1.144","journal-title":"World J Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2020.100531","article-title":"Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives","volume":"34","author":"Oberbauer R","year":"2020","unstructured":"Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L, Budde K. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives. Transplant Rev (Orlando). 2020, 34:100531. 10.1016\/j.trre.2020.100531","journal-title":"Transplant Rev (Orlando)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2023.01.003","article-title":"Immunosuppression monitoring\u2014what clinician needs to know?","volume":"13","author":"Wadhawan M","year":"2023","unstructured":"Wadhawan M, Gupta C. Immunosuppression monitoring\u2014what clinician needs to know?. J Clin Exp Hepatol. 2023, 13:691-7. 10.1016\/j.jceh.2023.01.003","journal-title":"J Clin Exp Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34410","article-title":"BK polyomavirus-induced nephropathy in native kidney","volume":"15","author":"Munjal RS","year":"2023","unstructured":"Munjal RS, Munjal J, Gandhi P, Gupta N. BK polyomavirus-induced nephropathy in native kidney. Cureus. 2023, 15:e34410. 10.7759\/cureus.34410","journal-title":"Cureus"},{"key":"ref6","article-title":"Tacrolimus","author":"Araya AA","year":"2023","unstructured":"Araya AA, Tasnif Y. Tacrolimus. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.981838","article-title":"Cardiovascular effects of immunosuppression agents","volume":"9","author":"Elezaby A","year":"2022","unstructured":"Elezaby A, Dexheimer R, Sallam K. Cardiovascular effects of immunosuppression agents. Front Cardiovasc Med. 2022, 9:981838. 10.3389\/fcvm.2022.981838","journal-title":"Front Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest DS","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. Am J Kidney Dis. 2023, 81:591-605. 10.1053\/j.ajkd.2022.10.014","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2016.09.010","article-title":"Syndromes of thrombotic microangiopathy","volume":"101","author":"Shatzel JJ","year":"2017","unstructured":"Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. Med Clin North Am. 2017, 101:395-415. 10.1016\/j.mcna.2016.09.010","journal-title":"Med Clin North Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry","volume":"1","author":"Arnold DM","year":"2017","unstructured":"Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, Kelton JG. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv. 2017, 1:2414-20. 10.1182\/bloodadvances.2017010942","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13954","article-title":"Diagnosis and treatment of thrombotic microangiopathy","volume":"44 Suppl 1","author":"Thompson GL","year":"2022","unstructured":"Thompson GL, Kavanagh D. Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol. 2022, 44 Suppl 1:101-13. 10.1111\/ijlh.13954","journal-title":"Int J Lab Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12048","article-title":"Tacrolimus\u2010induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients","volume":"43","author":"Nwaba A","year":"2013","unstructured":"Nwaba A, MacQuillan G, Adams LA et. al. Tacrolimus\u2010induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients. Intern Med J. 2013, 43:328-33. 10.1111\/imj.12048","journal-title":"Intern Med J"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201710001-02212","article-title":"Calcineurin inhibitor-induced microangiopathy after liver transplantation","volume":"112","author":"Hassan M","year":"2017","unstructured":"Hassan M, Selim R, Salgia R. Calcineurin inhibitor-induced microangiopathy after liver transplantation. Am J Gastroenterol. 2017, 112:1216-7.","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.08.915","article-title":"Tacrolimus in renal transplant and the development of thrombotic microangiopathy","volume":"158","author":"Aldrete K","year":"2020","unstructured":"Aldrete K, Taylor K, Dong J. Tacrolimus in renal transplant and the development of thrombotic microangiopathy. Chest. 2020, 158:A984.","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620947266","article-title":"The use of eculizumab in tacrolimus-induced thrombotic microangiopathy","volume":"8","author":"Gabr JB","year":"2020","unstructured":"Gabr JB, Bilal H, Mirchia K, Perl A. The use of eculizumab in tacrolimus-induced thrombotic microangiopathy. J Investig Med High Impact Case Rep. 2020, 8:10.1177\/2324709620947266","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2016.1151037","article-title":"Clinical determinants of calcineurin inhibitor disposition: a mechanistic review","volume":"48","author":"Vanhove T","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016, 48:88-112. 10.3109\/03602532.2016.1151037","journal-title":"Drug Metab Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1325","article-title":"Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?","volume":"59","author":"Campagne O","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?. J Clin Pharmacol. 2019, 59:309-25. 10.1002\/jcph.1325","journal-title":"J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu M","year":"2018","unstructured":"Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018, 19:513-22. 10.2174\/1389200219666180129151948","journal-title":"Curr Drug Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki E","year":"2017","unstructured":"Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Bone Marrow Transplant. 2017, 52:1355-60. 10.1038\/bmt.2017.39","journal-title":"Bone Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0327","article-title":"The differential diagnosis and treatment of thrombotic microangiopathies","volume":"115","author":"Bommer M","year":"2018","unstructured":"Bommer M, W\u00f6lfle-Guter M, Bohl S, Kuchenbauer F. The differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int. 2018, 115:327-34. 10.3238\/arztebl.2018.0327","journal-title":"Dtsch Arztebl Int"},{"key":"ref21","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou T","year":"2020","unstructured":"Chatzikonstantinou T, Gavriilaki M, Anagnostopoulos A, Gavriilaki E. An update in drug-induced thrombotic microangiopathy. Front Med (Lausanne). 2020, 7:212.","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain R","year":"2017","unstructured":"Gosain R, Gill A, Fuqua J, et al.. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep. 2017, 5:1926-30. 10.1002\/ccr3.1214","journal-title":"Clin Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani S","year":"2013","unstructured":"Shayani S, Palmer J, Stiller T, et al.. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013, 19:298-304. 10.1016\/j.bbmt.2012.10.006","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25874","article-title":"Tacrolimus-induced thrombotic microangiopathy after orthotopic heart transplant: a case report","volume":"14","author":"Gill R","year":"2022","unstructured":"Gill R, Meghrajani V. Tacrolimus-induced thrombotic microangiopathy after orthotopic heart transplant: a case report. Cureus. 2022, 14:e25874. 10.7759\/cureus.25874","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho VT","year":"2005","unstructured":"Ho VT, Cutler C, Carter S, et al.. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005, 11:571-5. 10.1016\/j.bbmt.2005.06.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group","volume":"92","author":"Ruutu T","year":"2007","unstructured":"Ruutu T, Barosi G, Benjamin RJ, et al.. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group. Haematologica. 2007, 92:95-100. 10.3324\/haematol.10699","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele S","year":"2015","unstructured":"Jodele S, Laskin BL, Dandoy CE, et al.. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015, 29:191-204. 10.1016\/j.blre.2014.11.001","journal-title":"Blood Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho BS","year":"2010","unstructured":"Cho BS, Yahng SA, Lee SESSE, et al.. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010, 90:918-26. 10.1097\/TP.0b013e3181f24e8d","journal-title":"Transplantation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4172\/2329-8820.1000152","article-title":"Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when?","volume":"2","author":"Uderzo C","year":"2014","unstructured":"Uderzo C, Jodele S, Missiry M, Ciceri F, Busca A, Bacigalupo A, Corbacioglu S. Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when?. J Bone Marrow Res. 2014, 2:3. 10.4172\/2329-8820.1000152","journal-title":"J Bone Marrow Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li A","year":"2019","unstructured":"Li A, Wu Q, Davis C, et al.. Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant. 2019, 25:570-6. 10.1016\/j.bbmt.2018.10.015","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava F","year":"2014","unstructured":"Nava F, Cappelli G, Mori G, et al.. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. Transplant Proc. 2014, 46:2263-8. 10.1016\/j.transproceed.2014.07.062","journal-title":"Transplant Proc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01601.x","article-title":"Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation","volume":"16","author":"Czubkowski P","year":"2012","unstructured":"Czubkowski P, Paw\u0142owska J, Jankowska I, Teisseyre M, Kami\u0144ska D, Markiewicz M, Ry\u017cko J. Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation. Pediatr Transplant. 2012, 16:E261-4. 10.1111\/j.1399-3046.2011.01601.x","journal-title":"Pediatr Transplant"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.11.020","article-title":"Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment","volume":"13","author":"Oran B","year":"2007","unstructured":"Oran B, Donato M, Aleman A, et al.. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007, 13:469-77. 10.1016\/j.bbmt.2006.11.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-007351","article-title":"Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient","volume":"2013","author":"Boyer NL","year":"2013","unstructured":"Boyer NL, Niven A, Edelman J. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. BMJ Case Rep. 2013, 2013:bcr2012007351. 10.1136\/bcr-2012-007351","journal-title":"BMJ Case Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-008-0037-6","article-title":"Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus","volume":"12","author":"Saito M","year":"2008","unstructured":"Saito M, Satoh S, Kagaya H, et al.. Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus. Clin Exp Nephrol. 2008, 12:312-5. 10.1007\/s10157-008-0037-6","journal-title":"Clin Exp Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22861","article-title":"Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus","volume":"57","author":"Rosenthal J","year":"2011","unstructured":"Rosenthal J, Pawlowska A, Bolotin E, Cervantes C, Maroongroge S, Thomas SH, Forman SJ. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer. 2011, 57:142-6. 10.1002\/pbc.22861","journal-title":"Pediatr Blood Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina G","year":"2015","unstructured":"Cortina G, Trojer R, Waldegger S, Schneeberger S, Gut N, Hofer J. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. Pediatr Nephrol. 2015, 30:693-7. 10.1007\/s00467-014-3036-8","journal-title":"Pediatr Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young JA","year":"2021","unstructured":"Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant. 2021, 56:1805-17. 10.1038\/s41409-021-01283-0","journal-title":"Bone Marrow Transplant"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler ML","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, et al.. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023, 29:151-63. 10.1016\/j.jtct.2022.11.015","journal-title":"Transplant Cell Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000092522.36410.D0","article-title":"Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation","volume":"77","author":"Paramesh AS","year":"2004","unstructured":"Paramesh AS, Grosskreutz C, Florman SS, Gondolesi GE, Sharma S, Kaufman SS, Fishbein TM. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation. 2004, 77:129-31. 10.1097\/01.TP.0000092522.36410.D0","journal-title":"Transplantation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(03)00210-0","article-title":"Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients","volume":"35","author":"Russ GR","year":"2003","unstructured":"Russ GR, Campbell S, Chadban S, et al.. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc. 2003, 35:S115-7. 10.1016\/S0041-1345(03)00210-0","journal-title":"Transplant Proc"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1999.tb00627.x","article-title":"Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports","volume":"12","author":"Humar A","year":"1999","unstructured":"Humar A, Jessurun J, Sharp HL, Gruessner RW. Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports. Transplant Int. 1999, 12:387-90. 10.1111\/j.1432-2277.1999.tb00627.x","journal-title":"Transplant Int"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.04.005","article-title":"Belatacept and eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: case report","volume":"48","author":"Merola J","year":"2016","unstructured":"Merola J, Yoo PS, Schaub J, et al.. Belatacept and eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: case report. Transplant Proc. 2016, 48:3106-8. 10.1016\/j.transproceed.2016.04.005","journal-title":"Transplant Proc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/191015-beyond-immunosuppression-the-intricate-relationship-between-tacrolimus-and-microangiopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:38Z","timestamp":1707509438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/191015-beyond-immunosuppression-the-intricate-relationship-between-tacrolimus-and-microangiopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":43,"URL":"https:\/\/doi.org\/10.7759\/cureus.49351","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}